Sex (Allegedly), Lies (Allegedly) And Videotape

The team discuss whether revelations about a covertly filmed sex tape really matter to Glaxo.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Owain Bennallack is joined by Mark Rogers and Nate Weisshaar to discuss whether revelations about a covertly filmed sex tape really matter in the long-running fraud saga faced by GlaxoSmithKline (LSE: GSK) in China.

The scandal continues with a look at the latest allegations leveled at embattled bank Barclays (LSE: BARC), before the team moves on to calmer waters to consider whether the higher annual allowances now in force for ISAs make them superior to pensions.

Plus three shares the team are watching right now: Rightmove (LSE: RMV), Ocado (LSE: OCDO) and Berkeley Group (LSE: BKG).

Should you invest £1,000 in M&G right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if M&G made the list?

See the 6 stocks

But here’s another bargain investment that looks absurdly dirt-cheap:

Like buying £1 for 31p

This seems ridiculous, but we almost never see shares looking this cheap. Yet this Share Advisor pick has a price/book ratio of 0.31. In plain English, this means that investors effectively get in on a business that holds £1 of assets for every 31p they invest!

Of course, this is the stock market where money is always at risk — these valuations can change and there are no guarantees. But some risks are a LOT more interesting than others, and at The Motley Fool we believe this company is amongst them.

What’s more, it currently boasts a stellar dividend yield of around 10%, and right now it’s possible for investors to jump aboard at near-historic lows. Want to get the name for yourself?

See the full investment case

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

The Motley Fool has recommended shares in GlaxoSmithKline.

More on Money Talk Podcast Archives

Money Talk Podcast Archives

What You Should Really Worry About

Owain, Mark and Nate debate whether terrible events in far-flung countries are really likely to impact your investments.

Read more »

Money Talk Podcast Archives

Investing In High-Growth Shares

Owain Bennallack is joined by US Fool Max Keeler to talk about high-growth disruptive companies.

Read more »

Money Talk Podcast Archives

Should You Buy Shares In TSB?

Owain Bennallack debates the pros and cons of investing in the TSB spin-off with Nate Weisshaar and Mark Rogers.

Read more »

Money Talk Podcast Archives

Time To Build A Position In The Housebuilders?

Owain and Nate discuss the housing bubble, IPOs, the state of the FTSE 100 (INDEXFTSE:UKX) as well as HSBC and…

Read more »

Money Talk Podcast Archives

Should You Join In The Frenzy For Big Pharma?

Owain Bennallack is joined by Nate Weisshaar and Nathan Parmelee.

Read more »

Money Talk Podcast Archives

Are Plunging Tech Shares A Buying Opportunity?

Owain, Mark and Nate discuss the tech share sell-off.

Read more »

Money Talk Podcast Archives

The Budget’s Big Breaks For Investors

Owain Bennallack dissects the fallout from this year's Budget with Nate Weisshaar and Mark Rogers.

Read more »

Money Talk Podcast Archives

Could World War 3 Curb Your Returns?

Owain Bennallack talks cheap Russian stocks with Nate Weisshaar and Mark Rogers.

Read more »